A5020932704- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Genetic Neurodegenerative Diseases
- Botulinum Toxin and Related Neurological Disorders
- Neuroscience and Neural Engineering
- Transcranial Magnetic Stimulation Studies
- Autism Spectrum Disorder Research
- Dysphagia Assessment and Management
- Nuclear Receptors and Signaling
- Neuroinflammation and Neurodegeneration Mechanisms
- Cerebral Palsy and Movement Disorders
- Voice and Speech Disorders
- RNA regulation and disease
- Glycogen Storage Diseases and Myoclonus
- Tryptophan and brain disorders
- Functional Brain Connectivity Studies
- Immune Cell Function and Interaction
- Hereditary Neurological Disorders
- Balance, Gait, and Falls Prevention
- Diabetes Treatment and Management
- Obsessive-Compulsive Spectrum Disorders
- Retinal Imaging and Analysis
- Peripheral Neuropathies and Disorders
- Assistive Technology in Communication and Mobility
- Older Adults Driving Studies
University of Florida
2017-2025
Florida College
2017-2024
University of Florida Health
2020-2024
Albany Medical Center Hospital
2012-2022
Creative Commons
2021
Neurological Surgery
2020
Clínica Alemana
2019
Hospital Padre Hurtado
2019
Universidad del Desarrollo
2019
Michigan State University
2018
There is a critical need for careful and independent validation of reported symptomatic efficacy dopaminergic biomarker changes induced by nilotinib in Parkinson disease (PD).To assess safety tolerability participants with moderately advanced PD. Secondary exploratory objectives were to its affect on PD disability, pharmacokinetics, cerebrospinal fluid (CSF) penetration, biomarkers.This was 6-month, multicenter, randomized parallel-group, double-blind, placebo-controlled trial. Recruitment...
Objective: To examine the short- and long-term clinical outcomes of bilateral subthalamic nucleus (STN) globus pallidus internus (GPi) deep brain stimulation (DBS) on gait axial symptoms in Parkinson's disease (PD) patients. Available data has been inconsistent mostly short-term regarding effect both targets symptoms. We aimed to identify potential target specific differences at three-year follow-up from a large single center experience. Methods: retrospectively reviewed (6-month follow-up)...
Abstract The pathophysiology of dystonic tremor and essential remains partially understood. In patients with medication-refractory or tremor, deep brain stimulation (DBS) targeting the thalamus posterior subthalamic area has evolved into a promising treatment option. However, optimal DBS targets for these disorders unknown. This retrospective study explored in using combination volumes tissue activated estimation functional structural connectivity analyses. We included 20 who underwent...
We estimate that 208,000 deep brain stimulation (DBS) devices have been implanted to address neurological and neuropsychiatric disorders worldwide. DBS Think Tank presenters pooled data determined expanded in its scope has applied multiple an effort modulate neural circuitry. The was founded 2012 providing a space where clinicians, engineers, researchers from industry academia discuss current emerging technologies logistical ethical issues facing the field. emphasis is on cutting edge...
Abstract Parkinson’s disease is the world’s fastest-growing neurological disorder. Research to elucidate mechanisms of and automate diagnostics would greatly improve treatment patients with disease. Current diagnostic methods are expensive have limited availability. Considering insidious preclinical onset progression disease, a desirable screening should be diagnostically accurate even before symptoms allow medical interventions. We highlight retinal fundus imaging, often termed window...
The annual Deep Brain Stimulation (DBS) Think Tank provides a focal opportunity for multidisciplinary ensemble of experts in the field neuromodulation to discuss advancements and forthcoming opportunities challenges field. proceedings fifth summarize progress neurotechnology techniques treatment range neuropsychiatric conditions including Parkinson's disease, dystonia, essential tremor, Tourette syndrome, obsessive compulsive disorder, epilepsy cognitive motor disorders. Each section this...
The Seventh Annual Deep Brain Stimulation (DBS) Think Tank held on September 8th of 2019 addressed the most current (1) use and utility complex neurophysiological signals for development adaptive neurostimulation to improve clinical outcomes; (2) Advancements in recent neuromodulation techniques treat neuropsychiatric disorders; (3) New developments optogenetics DBS; (4) augmented virtual reality neuromodulation; (5) commercially available technologies (6) ethical issues arising from...
Parkinson's disease (PD) is marked by a loss of dopamine neurons, decreased transporter (DAT) and tyrosine hydroxylase (TH) expression. However, this validation approach cannot be used for diagnostic, drug effectiveness or investigational purposes in human patients because midbrain tissue accessible postmortem. PD pathology affects both the central nervous peripheral immune systems. Therefore, we immunophenotyped blood samples presence myeloid derived suppressor cells (MDSCs) discovered that DAT
DBS Think Tank IX was held on August 25–27, 2021 in Orlando FL with US based participants largely person and overseas joining by video conferencing technology. The founded 2012 provides an open platform where clinicians, engineers researchers (from industry academia) can freely discuss current emerging deep brain stimulation (DBS) technologies as well the logistical ethical issues facing field. consensus among speakers that expanded its scope has been applied to multiple disorders effort...
Deep brain stimulation (DBS) is an emerging and effective therapy for Parkinson's disease (PD). However, little known about its utilization, surgical populations, centers, coverages, regional balance, influential factors. This large-scale multicenter cross-sectional study was conducted using a national census involving 74 Chinese centers. National DBS populations centers PD were investigated in 1997-2021, sociodemographic features, related resources, insurance policies 2020 explored. Since...
Abstract Alzheimer’s Disease (AD) is a progressive neurodegenerative disease and the leading cause of dementia. Early diagnosis critical for patients to benefit from potential intervention treatment. The retina has emerged as plausible diagnostic site AD detection owing its anatomical connection with brain. However, existing AI models this purpose have yet provide rational explanation behind their decisions not been able infer stage disease’s progression. Along direction, we propose novel...
The ventral intermediate nucleus (VIM) is the target of choice for Essential Tremor (ET) deep brain stimulation (DBS). Renewed interest in caudal zona incerta (cZI) tremor control has recently emerged and some groups believe this approach may address long-term reduction benefit seen with VIM-DBS.To compare clinical outcomes DBS programming between VIM cZI neurostimulation ET-DBS patients.A retrospective review 53 leads from 47 patients was performed. Patients were classified into or...
Abstract Objective To compare the efficacy of subthalamic nucleus (STN) and globus pallidus internus (GPi) deep brain stimulation (DBS) on reducing levodopa‐induced dyskinesia (LID) in Parkinson’s disease, to explore potential underlying mechanisms. Methods We retrospectively assessed clinical outcomes 43 patients with preoperative LID who underwent DBS targeting STN (20/43) or GPi (23/43). The primary outcome was change from baseline Unified Dyskinesia Rating Scale (UDysRS) secondary...
The globus pallidus internus (GPi) region has evolved as a potential target for deep brain stimulation (DBS) in Parkinson's disease (PD). DBS of the GPi (GPi DBS) is an established, safe and effective method addressing many motor symptoms associated with advanced PD. It important that clinicians fully understand this when considering individual patients. literature on PD been comprehensively reviewed, including anatomy, physiology pitfalls may be encountered during surgical targeting...
Introduction: Non-motor symptoms of Parkinson's disease (PD) such as gastrointestinal (GI) dysfunction are common, yet little is known about how modifying dietary intake impacts PD symptoms. The aim this study in individuals with was to determine whether a Mediterranean diet intervention feasible and affects GI function, intestinal permeability fecal microbial communities. Methods: A single-arm, 5-week conducted eight people PD. Daily weekly questionnaires were administered changes Urine...